Pomdoctor Limited

What they do

POMDOCTOR operates a platform where registered doctors can conduct medical prescription diagnoses and treatments after passing qualification verifications and background checks. The company tracks metrics such as contracted doctors, doctors issuing prescriptions, mature doctors, registered patients, and gross merchandise value, indicating a marketplace model for medical services and pharmaceutical products.

Revenue drivers

• Pharmaceutical product sales — Revenue is generated from orders for pharmaceutical products placed on the platform, though the filing excerpts provided do not break out exact segment revenue figures.
• Medical consultation services — The platform facilitates doctor-patient consultations, which may generate service fees, but the source material does not specify the revenue contribution of this line.
• GMV-based transactions — GMV represents the total value of all orders for products and services placed with the company, but the filing excerpts do not provide a breakdown of revenue by product or service.

Recent performance

For fiscal year 2025, POMDOCTOR reported annual revenue of $57.2 million, a net loss of $18.7 million, and diluted loss per share of $3.14. Operating cash flow was negative $21.2 million. As of December 31, 2025, the company had total assets of $15.4 million, total liabilities of $84.2 million, and shareholder equity of negative $64.9 million. Cash and equivalents stood at $1.4 million.

Strategy

The filing excerpts provided do not include management's discussion and analysis or forward-looking strategy statements. As a result, specific strategic priorities, investments, or stated direction cannot be summarized from the available material. The company's focus appears to be on expanding its online medical platform and doctor network based on the defined operating metrics, but no explicit strategy is detailed in the provided excerpts.

Risks

• Severe financial distress — The company reported negative shareholder equity of $64.9 million and total liabilities of $84.2 million against total assets of $15.4 million as of December 31, 2025, indicating a highly leveraged and insolvent balance sheet.
• Going concern uncertainty — With only $1.4 million in cash and equivalents and negative operating cash flow of $21.2 million for 2025, the company may lack sufficient liquidity to fund operations.
• Regulatory risk in China — As a China-based company, POMDOCTOR is subject to PRC laws and regulations, including those related to online medical services and pharmaceutical sales, which could change and adversely affect its business.
• Reliance on doctor network — The platform's success depends on attracting and retaining contracted doctors who can issue prescriptions; failure to maintain or grow this network could reduce transaction activity.

Outlook

The filing excerpts provided do not contain management's outlook or guidance for future periods. Therefore, no specific forward-looking statements can be summarized. Investors should refer to the full 20-F filing for any management commentary on future prospects.